Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$32.52 +2.00%

+$0.69 today

Market cap
$6.73B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.73M

Average 1.84M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$407.31M

FY 2026 · Annual

Investing Cash Flow

-$8,000.00

FY 2026 · Annual

Financing Cash Flow

$595.76M

FY 2026 · Annual

+31.1% YoY

Cash Flow Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(156.73M)(210.96M)(259.34M)(413.84M)(505.61M)
Depreciation & Amortization126K193K231K377K409K
Deferred Income Tax00000
Stock-Based Compensation34.24M32.3M41.12M49.49M55.72M
Change in Working Capital15.14M(10.85M)2.63M(12.03M)42.06M
Accounts Receivables(11.72M)12.23M(4.56M)2.97M(1.4M)
Inventory00000
Accounts Payables16.25M(17.12M)5.78M10.68M(10.25M)
Other Working Capital10.61M(5.95M)1.41M(25.69M)53.72M
Other Non-Cash Items1.11M1.13M1.13M133K99K
Operating Cash Flow(106.11M)(188.19M)(214.23M)(375.87M)(407.31M)
Capital Expenditures(254K)(197K)(360K)(759K)(8K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(254K)(197K)(360K)(759K)(8K)
Debt Repayment00000
Common Stock Issued129K70.5M472.75M450M596.26M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities200M385K(318K)4.49M(504K)
Financing Cash Flow200.13M70.89M472.43M454.49M595.76M
Effect of Forex Changes(92K)220K993K747K(299K)
Net Change in Cash93.67M(117.29M)258.83M78.61M188.14M
Free Cash Flow(106.37M)(188.39M)(214.59M)(376.63M)(407.32M)

Free Cash Flow

Net Income to FCF bridge

FY2026

= Net Income-$505.6M
+ D&A$409.0K
+ Stock-Based Comp$55.7M
+ Deferred Tax$0
+ Working Capital$42.1M
+ Other Non-Cash$99.0K
= Operating Cash Flow-$407.3M
- Capex-$8.0K
= Free Cash Flow-$407.3M

Analysis

FY2026 free cash flow is -$407.3M. FCF conversion is 80.6% of net income. Operating cash flow was -$407.3M, with capex of -$8.0K. The largest bridge item is Stock-Based Comp at $55.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
S-3ASRS-3ASR filingNov 9, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
4Statement of changes in beneficial ownershipOct 30, 2026

Does IMVT generate free cash flow?

Immunovant, Inc. (IMVT) generated -$407.32M of free cash flow in fiscal 2026.

How much operating cash flow does IMVT produce?

Operating cash flow was -$407.31M, before capital expenditures of $8,000.00.